These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 27175979)

  • 1. Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches.
    Lund-Palau H; Turnbull AR; Bush A; Bardin E; Cameron L; Soren O; Wierre-Gore N; Alton EW; Bundy JG; Connett G; Faust SN; Filloux A; Freemont P; Jones A; Khoo V; Morales S; Murphy R; Pabary R; Simbo A; Schelenz S; Takats Z; Webb J; Williams HD; Davies JC
    Expert Rev Respir Med; 2016 Jun; 10(6):685-97. PubMed ID: 27175979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
    Sousa AM; Monteiro R; Pereira MO
    Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2009 Oct; (4):CD004197. PubMed ID: 19821321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication of early Pseudomonas infection in cystic fibrosis.
    Lee TW
    Chron Respir Dis; 2009; 6(2):99-107. PubMed ID: 19411571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa and the airways disease of cystic fibrosis.
    Hata JS; Fick RB
    Clin Chest Med; 1988 Dec; 9(4):679-89. PubMed ID: 3148384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.
    Troxler RB; Hoover WC; Britton LJ; Gerwin AM; Rowe SM
    Pediatr Pulmonol; 2012 Nov; 47(11):1113-22. PubMed ID: 22496040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptome Analysis of Pseudomonas aeruginosa Biofilm Infection in an
    Harrington NE; Littler JL; Harrison F
    Appl Environ Microbiol; 2022 Feb; 88(3):e0178921. PubMed ID: 34878811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Wood DM; Smyth AR
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004197. PubMed ID: 16437476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
    Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR;
    Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
    Langan KM; Kotsimbos T; Peleg AY
    Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
    Taccetti G; Campana S; Festini F; Mascherini M; Döring G
    Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Smith S; Ratjen F; Remmington T; Waters V
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa Volatilome Characteristics and Adaptations in Chronic Cystic Fibrosis Lung Infections.
    Davis TJ; Karanjia AV; Bhebhe CN; West SB; Richardson M; Bean HD
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33028687
    [No Abstract]   [Full Text] [Related]  

  • 20. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.
    Bhagirath AY; Li Y; Somayajula D; Dadashi M; Badr S; Duan K
    BMC Pulm Med; 2016 Dec; 16(1):174. PubMed ID: 27919253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.